Approaches aimed at activating RIG-I within cancers are being explored as novel therapeutic strategies to generate an inflammatory tumor microenvironment and to facilitate cytotoxic T-cell cross-priming and infiltration (63, 64). The gene discussed is RIGI; the disease is cancer.